Heron Therapeutics Inc (NASDAQ:HRTX) shares dropped 0.2% on Thursday . The company traded as low as $29.30 and last traded at $30.95. Approximately 33,849 shares traded hands during trading, a decline of 96% from the average daily volume of 944,129 shares. The stock had previously closed at $31.00.

HRTX has been the subject of a number of research analyst reports. Cantor Fitzgerald raised their price objective on Heron Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, July 19th. Oppenheimer raised their price objective on Heron Therapeutics from $34.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, June 22nd. Evercore ISI raised their price objective on Heron Therapeutics from $56.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, June 21st. BidaskClub lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 22nd. Finally, Mizuho restated a “buy” rating and set a $41.00 price objective on shares of Heron Therapeutics in a research report on Friday, June 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and an average price target of $50.50.

The stock has a market capitalization of $2.54 billion, a P/E ratio of 8.32 and a beta of 1.44.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. The company had revenue of $17.28 million during the quarter, compared to analyst estimates of $12.82 million. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. The firm’s revenue was up 103.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.80) earnings per share. equities analysts predict that Heron Therapeutics Inc will post -2.2 earnings per share for the current year.

In related news, Director Kevin C. Tang sold 2,695,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total value of $96,346,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Kimberly Manhard sold 6,000 shares of Heron Therapeutics stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $37.53, for a total value of $225,180.00. Following the completion of the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at approximately $225,180. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,085,469 shares of company stock valued at $111,612,708. 16.20% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Quantbot Technologies LP purchased a new position in shares of Heron Therapeutics during the first quarter valued at approximately $117,000. Cubist Systematic Strategies LLC purchased a new position in shares of Heron Therapeutics during the second quarter valued at approximately $151,000. SG Americas Securities LLC purchased a new position in shares of Heron Therapeutics during the first quarter valued at approximately $183,000. NewSquare Capital LLC purchased a new position in shares of Heron Therapeutics during the second quarter valued at approximately $211,000. Finally, Credit Agricole S A purchased a new position in shares of Heron Therapeutics during the first quarter valued at approximately $240,000.

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: Earnings Per Share (EPS)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.